Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Tonix Pharmaceuticals (Nasdaq: TNXP) will participate in two investor events: a fireside chat at the Canaccord Genuity 46th Annual Growth Conference in Boston on August 11, 2026 at 1:30–1:55 p.m. ET, and 1x1 meetings at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on September 16, 2026.
Both events feature President and CEO Seth Lederman, M.D.. A live webcast and replay will be accessible via the News & Events section of Tonix’s investor website. Tonix is a commercial-stage biotech focused on CNS disorders, infectious diseases, immunology, and rare diseases, with marketed products for fibromyalgia and acute migraine.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BERKELEY HEIGHTS, N.J., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biotechnology company, today announced that the management team will participate in two upcoming investor conferences in August and September 2026.
Canaccord Genuity 46th Annual Growth Conference
Fireside Chat
Presenter: Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals
Location: Boston, Massachusetts
Date: August 11, 2026
Presentation Time: 1:30-1:55 p.m. ET
Morgan Stanley 24th Annual Global Healthcare Conference
1x1 Meetings
Participant: Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals
Location: New York, New York
Date: September 16, 2026
A live webcast and replay will be available under the News & Events tab in the Investors section of the Tonix website at https://ir.tonixpharma.com/.
Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) disorders, infectious diseases, immunology conditions, and rare diseases where there exists high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8mg), the Company's flagship internally conceived and developed medicine, is the first treatment for fibromyalgia in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® SymTouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is extending the science behind TONMYA in Phase 2 clinical studies to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of infectious disease programs, including monoclonal antibody, Phase 2 ready TNX-4800 (anti-OspA mAb) for Lyme disease prevention in the U.S. and TNX-801 (horsepox, live virus vaccine), a vaccine in development for the prevention of mpox and smallpox. Within immunology, Tonix is developing TNX-1500 (anti-CD40L mAb), a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. Finally, the Company's rare disease portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome. To learn more, visit www.tonixpharma.com.
*Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.
Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners.
Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 including those relating to the completion of the offering, the satisfaction of customary closing conditions, the intended use of proceeds from the offering and other statements that are predictive in nature. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to successfully launch and commercialize TONMYA® and any of our approved products; risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on March 12, 2026, and periodic reports filed with the SEC on or after the date thereof. Tonix does not undertake an obligation to update or revise any forward-looking statement. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.
Contacts
Deborah Elson (Investors/Media)
Tonix Pharmaceuticals
deborah.elson@tonixpharma.com
investor.relations@tonixpharma.com
Brian Korb (Investors)
astr partners
(917) 653-5122
brian.korb@astrpartners.com
Andrea Cohen (Media)
Sam Brown Inc.
(917) 209-7163
andreacohen@sambrown.com
